someone will go... BUT WHO??

Quote

Anonymous

Guest
as we near the beginning of the end, there is no doubt that somebody will finally get the blame (other than a rep). I am sure that LC is not in Japan for some good sushi! The question is who will be asked to step down. In my oh so humble opinion, the options are (drum roll please):

A) Lonnell
B) Michael
c) Thomas K

The question is who do you blame for all the consistent blunders. Do you remember Zonegran (NOT ZONEGRAM!!) Colazal, Aricept ODT and we are still living in the A 23 mishap era? So... cast your votes early as a decision should be made by Friday!
 









Anonymous said:
as we near the beginning of the end, there is no doubt that somebody will finally get the blame (other than a rep). I am sure that LC is not in Japan for some good sushi! The question is who will be asked to step down. In my oh so humble opinion, the options are (drum roll please):

A) Lonnell
B) Michael
c) Thomas K

The question is who do you blame for all the consistent blunders. Do you remember Zonegran (NOT ZONEGRAM!!) Colazal, Aricept ODT and we are still living in the A 23 mishap era? So... cast your votes early as a decision should be made by Friday!
Click to expand...

There is only one common denominator!!!!

How can the field be blamed for brands that didn't even make it to market (lorcaserin, eritorin). So the field is not the common denominator.

OB is head of sales, he's not involved in brand approvals. So OB is not the common denominator.

Tk is over primary care, not oncology. There have been many blunders in oncology. So TK is not the common denominator.

LC - BINGO - The common denomintor in sales blunders and brand approvals across PC and Oncology. LC has failed big time!

So will LC step down on Friday and own up to his many failures or pass the buck. People will be let go, not doubt, but will the person responsible escape responsibility?
 



Anonymous said:
There is only one common denominator!!!!

How can the field be blamed for brands that didn't even make it to market (lorcaserin, eritorin). So the field is not the common denominator.

OB is head of sales, he's not involved in brand approvals. So OB is not the common denominator.

Tk is over primary care, not oncology. There have been many blunders in oncology. So TK is not the common denominator.

LC - BINGO - The common denomintor in sales blunders and brand approvals across PC and Oncology. LC has failed big time!

So will LC step down on Friday and own up to his many failures or pass the buck. People will be let go, not doubt, but will the person responsible escape responsibility?
Click to expand...


Highly probably based on past history and the fact that senior management has never been accountable for their actions. There will be many scapegoats, as usual.
 



Anonymous said:
Highly probably based on past history and the fact that senior management has never been accountable for their actions. There will be many scapegoats, as usual.
Click to expand...

There have been many blunders but only one person spans over all blunders - Mr. CEO, LC. If he remains in his job then it's obvious Eisai deserves a poor future.
 






I'm not sure some of you get it-----anyone with "sales" in their title (VP of Sales, National Director of Sales) has nothing to do with what we in-license or put money behind for research. Those decisions are made by different people, much higher up. With the list of setbacks here (Zonegran, Locarserin, Eritoran, Aloxi PONV, Lusedra, whatever that drug was we bought and then went generic), someone's head should roll, but it's not going to be anybody in sales or marketing.
 









Top Bottom
Back
Quote